Sanara MedTech (SMTI) FDA Approvals $35.13 -0.02 (-0.06%) As of 10/13/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest Sanara MedTech's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Sanara MedTech (SMTI). Over the past two years, Sanara MedTech has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as CellerateRX. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. CellerateRX FDA Regulatory Events CellerateRX is a drug developed by Sanara MedTech for the following indication: Surgical Powder in the Management of Spine Surgery Wounds. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - March 11,2026Publication Drug: CellerateRXAnnounced Date: March 11, 2026Indication: Surgical Powder in the Management of Spine Surgery WoundsAnnouncementSanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics.AI SummarySanara MedTech announced a peer‑reviewed study in the Journal of Medical Economics that evaluated the economic and clinical value of CellerateRX® Surgical Powder. Researchers used economic modeling to compare two groups of high‑comorbidity patients having complex spinal surgery: those who received CellerateRX as an adjunct to standard wound care and those who received standard care alone. The study tracked postoperative complications, hospital readmissions, and surgical revisions over one year. Clinical benefits were measured in quality‑adjusted life years (QALYs) and direct medical costs were expressed in 2025 U.S. dollars. The study found that adding CellerateRX led to both better health outcomes and overall cost savings versus standard care alone. Authors concluded CellerateRX can be a value‑enhancing part of the spine surgery care pathway, especially for patients who face higher risk of complications, by reducing complications, readmissions and costly revision procedures. Read Announcement Sanara MedTech FDA Events - Frequently Asked Questions Has Sanara MedTech received FDA approval? As of now, Sanara MedTech (SMTI) has not received any FDA approvals for its therapy in the last two years. What drugs has Sanara MedTech submitted to the FDA? In the past two years, Sanara MedTech (SMTI) has reported FDA regulatory activity for CellerateRX. What is the most recent FDA event for Sanara MedTech? The most recent FDA-related event for Sanara MedTech occurred on March 11, 2026, involving CellerateRX. The update was categorized as "Publication," with the company reporting: "Sanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics." What conditions do Sanara MedTech's current drugs treat? Currently, Sanara MedTech has one therapy (CellerateRX) targeting the following condition: Surgical Powder in the Management of Spine Surgery Wounds. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AgomAb Therapeutics FDA EventsAlkermes FDA EventsBeam Therapeutics FDA EventsBiomea Fusion FDA EventsBioNTech FDA EventsEnanta Pharmaceuticals FDA EventsEntera Bio FDA EventsImmuron FDA EventsKura Oncology FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsModerna FDA EventsPhio Pharmaceuticals FDA EventsPrelude Therapeutics FDA EventsRhythm Pharmaceuticals FDA EventsSAB Biotherapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies QuidelOrtho FDA Events Align Technology FDA Events Alpha Tau Medical FDA Events Artivion FDA Events PROCEPT BioRobotics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:SMTI last updated on 3/11/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredTrump's crypto bank just got approvedLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanara MedTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - March 11,2026Publication Drug: CellerateRXAnnounced Date: March 11, 2026Indication: Surgical Powder in the Management of Spine Surgery WoundsAnnouncementSanara MedTech Inc. announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX® Surgical Powder ("CellerateRX") in the Journal of Medical Economics.AI SummarySanara MedTech announced a peer‑reviewed study in the Journal of Medical Economics that evaluated the economic and clinical value of CellerateRX® Surgical Powder. Researchers used economic modeling to compare two groups of high‑comorbidity patients having complex spinal surgery: those who received CellerateRX as an adjunct to standard wound care and those who received standard care alone. The study tracked postoperative complications, hospital readmissions, and surgical revisions over one year. Clinical benefits were measured in quality‑adjusted life years (QALYs) and direct medical costs were expressed in 2025 U.S. dollars. The study found that adding CellerateRX led to both better health outcomes and overall cost savings versus standard care alone. Authors concluded CellerateRX can be a value‑enhancing part of the spine surgery care pathway, especially for patients who face higher risk of complications, by reducing complications, readmissions and costly revision procedures. Read Announcement
